These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25842049)

  • 21. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
    Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM
    Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.
    Sanchorawala V; Hoering A; Seldin DC; Finn KT; Fennessey SA; Sexton R; Mattar B; Safah HF; Holmberg LA; Dean RM; Orlowski RZ; Barlogie B
    Bone Marrow Transplant; 2013 Nov; 48(12):1537-42. PubMed ID: 23852321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
    Comenzo RL; Vosburgh E; Falk RH; Sanchorawala V; Reisinger J; Dubrey S; Dember LM; Berk JL; Akpek G; LaValley M; O'hara C; Arkin CF; Wright DG; Skinner M
    Blood; 1998 May; 91(10):3662-70. PubMed ID: 9573002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.
    Dispenzieri A; Seenithamby K; Lacy MQ; Kumar SK; Buadi FK; Hayman SR; Dingli D; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Johnston PB; Porrata LF; Patnaik MM; Hogan WJ; Gertz MA
    Bone Marrow Transplant; 2013 Oct; 48(10):1302-7. PubMed ID: 23604010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.
    Cibeira MT; Sanchorawala V; Seldin DC; Quillen K; Berk JL; Dember LM; Segal A; Ruberg F; Meier-Ewert H; Andrea NT; Sloan JM; Finn KT; Doros G; Blade J; Skinner M
    Blood; 2011 Oct; 118(16):4346-52. PubMed ID: 21828140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
    Huang X; Wang Q; Chen W; Zeng C; Chen Z; Gong D; Zhang H; Liu Z
    BMC Med; 2014 Jan; 12():2. PubMed ID: 24386911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
    Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
    J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis.
    Hayes-Lattin BM; Curtin PT; Fleming WH; Leis JF; Stepan DE; Schubach S; Maziarz RT
    Bone Marrow Transplant; 2002 Sep; 30(5):279-85. PubMed ID: 12209349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical investigation of primary amyloidosis with autologous hematopoietic stem cell transplantation].
    Qiu ZX; Wang MJ; Wang LH; Sun YH; Xu WL; Liu W; Ou JP; Dong YJ; Wang WS; Li Y; Yin Y; Liang ZY; Cen XN; Ren HY
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):187-90. PubMed ID: 22781604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.
    Tsukada N; Ikeda M; Shingaki S; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
    Int J Hematol; 2016 Mar; 103(3):299-305. PubMed ID: 26703787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee.
    Fuchida SI; Ogura M; Ishida T; Hata H; Handa H; Katoh N; Nakaseko C; Sunami K; Katayama Y; Nobata H; Oshiro K; Iida S; Sekijima Y; Naiki H; Shimazaki C
    Int J Hematol; 2023 Oct; 118(4):443-449. PubMed ID: 37515656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
    Cordes S; Gertz MA; Buadi FK; Lin Y; Lacy MQ; Kapoor P; Kumar SK; McCurdy A; Dispenzieri A; Dingli D; Hayman SR; Hogan WJ; Pruthi RK
    Blood Coagul Fibrinolysis; 2016 Jan; 27(1):101-8. PubMed ID: 26218969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation?
    Yoon JH; Kim HJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):588-597. PubMed ID: 28089879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.
    Skinner M; Sanchorawala V; Seldin DC; Dember LM; Falk RH; Berk JL; Anderson JJ; O'Hara C; Finn KT; Libbey CA; Wiesman J; Quillen K; Swan N; Wright DG
    Ann Intern Med; 2004 Jan; 140(2):85-93. PubMed ID: 14734330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.
    D'Souza A; Dispenzieri A; Wirk B; Zhang MJ; Huang J; Gertz MA; Kyle RA; Kumar S; Comenzo RL; Peter Gale R; Lazarus HM; Savani BN; Cornell RF; Weiss BM; Vogl DT; Freytes CO; Scott EC; Landau HJ; Moreb JS; Costa LJ; Ramanathan M; Callander NS; Kamble RT; Olsson RF; Ganguly S; Nishihori T; Kindwall-Keller TL; Wood WA; Mark TM; Hari P
    J Clin Oncol; 2015 Nov; 33(32):3741-9. PubMed ID: 26371138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation.
    Schönland SO; Lokhorst H; Buzyn A; Leblond V; Hegenbart U; Bandini G; Campbell A; Carreras E; Ferrant A; Grommisch L; Jacobs P; Kröger N; La Nasa G; Russell N; Zachee P; Goldschmidt H; Iacobelli S; Niederwieser D; Gahrton G; ;
    Blood; 2006 Mar; 107(6):2578-84. PubMed ID: 16293611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom.
    Sharpley FA; Petrie A; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Whelan CJ; Fontana M; Martinez-Naharro A; Quarta C; Hawkins PN; Wechalekar AD
    Br J Haematol; 2019 Dec; 187(5):642-652. PubMed ID: 31410841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Sher T; Dispenzieri A; Gertz MA
    Biol Blood Marrow Transplant; 2016 May; 22(5):796-801. PubMed ID: 26475727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.